Royce & Associates Reduces Stake in Travere Therapeutics

Hedge fund cuts position in biotech company by over two-thirds

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Royce & Associates LP, a prominent investment management firm, has decreased its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 67.7% during the third quarter, according to a recent disclosure with the Securities and Exchange Commission. The firm now owns 123,250 shares of the biopharmaceutical company's stock, down from 380,997 shares previously.

Why it matters

Travere Therapeutics is a San Diego-based biotech focused on developing therapies for rare kidney and genetic disorders. The reduction in Royce & Associates' position could signal a shift in investor sentiment around the company's prospects, though the reasons behind the move are not entirely clear.

The details

According to the filing, Royce & Associates sold 257,747 shares of Travere Therapeutics during the third quarter, leaving the firm with a remaining position valued at $2.95 million. The hedge fund now owns approximately 0.14% of the company's outstanding shares.

  • Royce & Associates reduced its Travere Therapeutics stake during the third quarter of 2026.

The players

Royce & Associates LP

A prominent investment management firm that has decreased its position in Travere Therapeutics.

Travere Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California, that is focused on developing therapies for rare kidney and genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Royce & Associates' stake in Travere Therapeutics could signal a shift in investor sentiment around the company's prospects, though the specific reasons behind the move are not entirely clear. As a biotech focused on rare diseases, Travere Therapeutics' future performance will likely depend on the success of its pipeline and regulatory approvals.